These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2045842)

  • 21. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation.
    Zetterqvist AV; Merlo J; Mulinari S
    PLoS Med; 2015 Feb; 12(2):e1001785. PubMed ID: 25689460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan.
    Rohra DK; Gilani AH; Memon IK; Perven G; Khan MT; Zafar H; Kumar R
    J Pharm Pharm Sci; 2006; 9(1):50-9. PubMed ID: 16849008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug advertisements in less-developed countries.
    Dal-Pizzol F
    Lancet; 2002 Apr; 359(9315):1439-40. PubMed ID: 11978373
    [No Abstract]   [Full Text] [Related]  

  • 25. Spurious and counterfeit drugs: a growing industry in the developing world.
    Gautam CS; Utreja A; Singal GL
    Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International regulation of the supply and use of pharmaceuticals.
    Medawar C
    Dev Dialogue; 1985; (2):15-37. PubMed ID: 12341045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Counterfeit medicines: a growing threat].
    Barbereau S
    Med Trop (Mars); 2006 Dec; 66(6):529-32. PubMed ID: 17286014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Essential and non-essential drugs marketed by the 20 largest European pharmaceutical companies in developing countries.
    Hartog R
    Soc Sci Med; 1993 Oct; 37(7):897-904. PubMed ID: 8211308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug maker to pay $430 million in fines, civil damages.
    FDA Consum; 2004; 38(4):36-7. PubMed ID: 15346583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevance of variation in use of terminology to define generic pharmaceutical products.
    Fonseca EM
    Rev Panam Salud Publica; 2015 Feb; 37(2):113-7. PubMed ID: 25915016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent multistate enforcement initiatives: prescription drug promotional practices.
    Woodward D
    Food Drug Law J; 1995; 50(2):295-300. PubMed ID: 10342997
    [No Abstract]   [Full Text] [Related]  

  • 32. Indigenous and multinational pharmaceutical companies.
    Lilja J
    Soc Sci Med; 1983; 17(16):1171-80. PubMed ID: 6623122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Private sector joins family planning effort.
    Front Lines; 1989 Dec; ():6, 13. PubMed ID: 12343476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA warns about fraudulent STD treatments.
    AIDS Patient Care STDS; 2008 Apr; 22(4):353. PubMed ID: 18434953
    [No Abstract]   [Full Text] [Related]  

  • 35. Government investigations in the pharmaceutical industry: off-label promotion, fraud and abuse, and false claims.
    Kalb PE; Bass IS
    Food Drug Law J; 1998; 53(1):63-70. PubMed ID: 11795337
    [No Abstract]   [Full Text] [Related]  

  • 36. Criminalizing knowledge: the perverse implications of the intended use regulations of off-label promotion prosecutions.
    Gentry G
    Food Drug Law J; 2009; 64(3):441-58. PubMed ID: 19999637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technology policy and planning in the Third World pharmaceutical sector: the Cuban and Caribbean community approaches.
    Thrupp LA
    Int J Health Serv; 1984; 14(2):189-216. PubMed ID: 6735538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. For U.S. drug companies' products sold in developing countries, labeling is often inadequate.
    Am J Hosp Pharm; 1994 Apr; 51(7):875-6. PubMed ID: 8017435
    [No Abstract]   [Full Text] [Related]  

  • 39. Antibiotic resistance in the tropics. 3. Medical responsibilities of the pharmaceutical industry with respect to use of antibiotics in the tropics.
    Salter AJ
    Trans R Soc Trop Med Hyg; 1989; 83(1):45-8. PubMed ID: 2690415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of pharmaceuticals in the total health care of developing countries.
    Hoekenga MT
    Am J Trop Med Hyg; 1983 May; 32(3):437-46. PubMed ID: 6859394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.